Evolent Health, Inc (NYSE:EVH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Evolent Health, Inc (NYSE:EVH) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $6.50.

Several analysts recently issued reports on the stock. Oppenheimer dropped their price objective on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, November 12th. BMO Capital Markets restated an “outperform” rating and issued a $3.50 price target on shares of Evolent Health in a research report on Wednesday. Citizens Jmp cut their price target on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a report on Tuesday, January 6th. JPMorgan Chase & Co. reduced their price objective on Evolent Health from $13.00 to $7.00 and set an “overweight” rating on the stock in a research report on Monday, November 17th. Finally, Truist Financial lowered their price objective on Evolent Health from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday.

Evolent Health Stock Down 2.0%

NYSE EVH opened at $3.26 on Tuesday. The business has a fifty day moving average price of $3.49 and a 200 day moving average price of $5.77. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33. The company has a market cap of $363.26 million, a P/E ratio of -0.63 and a beta of 0.27. Evolent Health has a one year low of $2.50 and a one year high of $12.06.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $468.72 million during the quarter, compared to analyst estimates of $468.48 million. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The company’s revenue for the quarter was down 27.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. Research analysts anticipate that Evolent Health will post 0.08 EPS for the current fiscal year.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: BTIG set a new $8.00 price target for EVH, signaling confidence that the stock has upside from current levels. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Positive Sentiment: UBS lowered its target to $5.00 but kept a “buy” rating, implying upside (reported as ~54% above the then-current price). UBS lowers price target to $5.00
• Positive Sentiment: Citigroup cut its target to $4.00 but maintained a “buy” rating, which suggests analysts still see recovery potential despite near-term weakness. Citigroup lowers price target to $4.00
• Positive Sentiment: Seeking Alpha published a bullish-themed piece arguing EVH is “cheap, levered, but ready to rebound,” which can attract value-oriented buyers. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Evolent announced executive participation in upcoming investor conferences with live webcasts — useful for transparency but unlikely to move the stock materially on its own. Evolent to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Yahoo Finance ran a roundup noting a sharp intraday move earlier; such coverage increases attention/volatility but doesn’t change fundamentals. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Neutral Sentiment: Royal Bank of Canada set a $3.00 target — a lower valuation point that may anchor some expectations but was published alongside other divergent targets. Evolent Health (NYSE:EVH) Given New $3.00 Price Target at Royal Bank Of Canada
• Neutral Sentiment: Needham published a $4.00 price target; another mid-range projection adding to the wide spread of analyst views. Evolent Health (NYSE:EVH) Given New $4.00 Price Target at Needham & Company LLC
• Negative Sentiment: KeyCorp lowered EVH to “Sector Weight” (a downgrade), which is a clear negative signal and likely contributed to selling pressure. Evolent Health (NYSE:EVH) Rating Lowered to “Sector Weight” at KeyCorp

Hedge Funds Weigh In On Evolent Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its stake in shares of Evolent Health by 88.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after buying an additional 1,194 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in Evolent Health by 4,000.0% in the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. Strs Ohio purchased a new position in Evolent Health in the first quarter worth approximately $47,000. Headlands Technologies LLC acquired a new stake in Evolent Health during the second quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in Evolent Health in the third quarter valued at $51,000.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.